Showing results (21-30 of 44) with videos related to
Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|July 10, 2017
Immune checkpoint inhibitors and elderly people: A reviewAmaury Daste, Charlotte Domblides, Marine Gross-Goupil, et al.Cancer Treatment Reviews|August 18, 2020
Current management and future perspectives of penile cancer: An updated reviewFlorent Peyraud, Clément Allenet, Marine Gross-Goupil, et al.BMC Cancer|July 14, 2023
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective studyAgathe Vienne, Laetitia Collet, Thomas Chevalier, et al.European Journal of Cancer (Oxford, England : 1990)|October 2, 2019
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckKhalil Saleh, Amaury Daste, Nicolas Martin, et al.Journal for Immunotherapy of Cancer|July 10, 2020
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohortByoung Chul Cho, Amaury Daste, Alain Ravaud, et al.European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neckKhalil Saleh, Anne Auperin, Nicolas Martin, et al.Cancer Medicine|June 3, 2021
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREMEThomas Chevalier, Amaury Daste, Esmaa Saada-Bouzid, et al.Journal for Immunotherapy of Cancer|April 9, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinomaAmaury Daste, Xiuning Le, Amani Makkouk, et al.Head & Neck|May 1, 2026
Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter StudyMarie Degrange, Mathilde Morisseau, Justin Michel, et al.Oncoimmunology|December 22, 2022
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumorsBao-Tram Thi Tran, Aurore Gelin, Sylvère Durand, et al.Pageof 5